Variant · Snv
FGFR2 S252W
CI-VAR-00004041Explore in graph →CIViC 5548
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38603650
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Salivary Gland Adenoid Cystic Carcinoma1 | ||||||||
| FGFR2 S252W | Erdafitinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13161In the phase II NCI-MATCH EAY131-K2 trial, a patient with high-grade adenoid cystic carcinoma of the submandibular gland harboring an FGFR2 S252W (p.Ser252Trp) mutation achieved a partial response to … (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.